Form 4 for BEAM Beam Therapeutics Inc.
Accepted 2025-04-03 00:00:00 ET · period of report 2025-04-01 · accession 0000950170-25-050857 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2025-04-03 | 2025-04-01 | BEAM | Evans John M. | CEO, Dir | S - Sale | $18.35 | -30.7K | 986.2K | -3% | -$562.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-04-01 | S | D | 30,663 | $18.35 | 986,249 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $17.76 to $18.38, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. (F3) Includes 753 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on March 31, 2025. |